Shots:
2025 marked a decisive inflection point for the global life sciences and biopharma industry. After several years defined by experimentation, abundant capital, and expansive innovation narratives, the industry entered a phase of disciplined execution.
Strategies were stress-tested, science was closely scrutinized, and only programs with clear biological rationale and operational readiness advanced.
Rather than…
